Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events

Priyanka A. Pophali, Jeffrey K. Klotz, Sawa Ito, Natasha A. Jain, Eleftheria Koklanaris, Robert Q. Le, Christopher Hourigan, Bipin N. Savani, Kamna Chawla, Sujata Shanbhag, A. John Barrett, Minoo Battiwalla

Research output: Contribution to journalArticle

Abstract

Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk factors (CVRFs) in 109 SCT survivors (62 males, 47 females; median age 34 years) five years or more after bone marrow (15) or T cell-depleted peripheral blood (94) SCT for CML (56), acute leukemia (29), MDS (13), and others (11). One death and two cardiovascular events were reported. At five and ten years after SCT, respectively, 44% and 52% had abnormal lipid profiles; 23% of 5-year survivors met the Adult Treatment Panel III threshold for dyslipidemia treatment, which is substantially higher than the age-matched general population. There were significant increases in prevalence of hypertension (p < 0.001), diabetes (p = 0.018), and body mass index (p = 0.044) after SCT compared with baseline. The Framingham general cardiovascular risk score (FGCRS) in males at five years after SCT projected a doubling (median 10.4% vs. 5.4%) in the 10-year risk of cardiovascular events. Females received HRT after SCT, and none had increased FGCRS. Chronic GVHD and C-reactive protein were not associated with CVRF at any time. All CVRFs stabilized between five and ten years after SCT. Thus, SCT survivors have sustained elevations in CVRFs. Males have a significantly increased risk of cardiovascular events in their second and third decade after SCT.

Original languageEnglish (US)
Pages (from-to)101-113
Number of pages13
JournalExperimental Hematology
Volume42
Issue number2
DOIs
StatePublished - Jan 1 2014
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Stem Cell Transplantation
Survivors
Peripheral Blood Stem Cell Transplantation
Dyslipidemias
Bone Marrow Cells
C-Reactive Protein
Leukemia
Body Mass Index
Cardiovascular Diseases
Hypertension
T-Lymphocytes
Lipids
Therapeutics

ASJC Scopus subject areas

  • Molecular Biology
  • Hematology
  • Genetics
  • Cell Biology
  • Cancer Research

Cite this

Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. / Pophali, Priyanka A.; Klotz, Jeffrey K.; Ito, Sawa; Jain, Natasha A.; Koklanaris, Eleftheria; Le, Robert Q.; Hourigan, Christopher; Savani, Bipin N.; Chawla, Kamna; Shanbhag, Sujata; Barrett, A. John; Battiwalla, Minoo.

In: Experimental Hematology, Vol. 42, No. 2, 01.01.2014, p. 101-113.

Research output: Contribution to journalArticle

Pophali, PA, Klotz, JK, Ito, S, Jain, NA, Koklanaris, E, Le, RQ, Hourigan, C, Savani, BN, Chawla, K, Shanbhag, S, Barrett, AJ & Battiwalla, M 2014, 'Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events', Experimental Hematology, vol. 42, no. 2, pp. 101-113. https://doi.org/10.1016/j.exphem.2013.07.003
Pophali, Priyanka A. ; Klotz, Jeffrey K. ; Ito, Sawa ; Jain, Natasha A. ; Koklanaris, Eleftheria ; Le, Robert Q. ; Hourigan, Christopher ; Savani, Bipin N. ; Chawla, Kamna ; Shanbhag, Sujata ; Barrett, A. John ; Battiwalla, Minoo. / Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events. In: Experimental Hematology. 2014 ; Vol. 42, No. 2. pp. 101-113.
@article{709a54815cc84ec1830defaf8792a1f2,
title = "Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events",
abstract = "Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk factors (CVRFs) in 109 SCT survivors (62 males, 47 females; median age 34 years) five years or more after bone marrow (15) or T cell-depleted peripheral blood (94) SCT for CML (56), acute leukemia (29), MDS (13), and others (11). One death and two cardiovascular events were reported. At five and ten years after SCT, respectively, 44{\%} and 52{\%} had abnormal lipid profiles; 23{\%} of 5-year survivors met the Adult Treatment Panel III threshold for dyslipidemia treatment, which is substantially higher than the age-matched general population. There were significant increases in prevalence of hypertension (p < 0.001), diabetes (p = 0.018), and body mass index (p = 0.044) after SCT compared with baseline. The Framingham general cardiovascular risk score (FGCRS) in males at five years after SCT projected a doubling (median 10.4{\%} vs. 5.4{\%}) in the 10-year risk of cardiovascular events. Females received HRT after SCT, and none had increased FGCRS. Chronic GVHD and C-reactive protein were not associated with CVRF at any time. All CVRFs stabilized between five and ten years after SCT. Thus, SCT survivors have sustained elevations in CVRFs. Males have a significantly increased risk of cardiovascular events in their second and third decade after SCT.",
author = "Pophali, {Priyanka A.} and Klotz, {Jeffrey K.} and Sawa Ito and Jain, {Natasha A.} and Eleftheria Koklanaris and Le, {Robert Q.} and Christopher Hourigan and Savani, {Bipin N.} and Kamna Chawla and Sujata Shanbhag and Barrett, {A. John} and Minoo Battiwalla",
year = "2014",
month = "1",
day = "1",
doi = "10.1016/j.exphem.2013.07.003",
language = "English (US)",
volume = "42",
pages = "101--113",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Male survivors of allogeneic hematopoietic stem cell transplantation have a long term persisting risk of cardiovascular events

AU - Pophali, Priyanka A.

AU - Klotz, Jeffrey K.

AU - Ito, Sawa

AU - Jain, Natasha A.

AU - Koklanaris, Eleftheria

AU - Le, Robert Q.

AU - Hourigan, Christopher

AU - Savani, Bipin N.

AU - Chawla, Kamna

AU - Shanbhag, Sujata

AU - Barrett, A. John

AU - Battiwalla, Minoo

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk factors (CVRFs) in 109 SCT survivors (62 males, 47 females; median age 34 years) five years or more after bone marrow (15) or T cell-depleted peripheral blood (94) SCT for CML (56), acute leukemia (29), MDS (13), and others (11). One death and two cardiovascular events were reported. At five and ten years after SCT, respectively, 44% and 52% had abnormal lipid profiles; 23% of 5-year survivors met the Adult Treatment Panel III threshold for dyslipidemia treatment, which is substantially higher than the age-matched general population. There were significant increases in prevalence of hypertension (p < 0.001), diabetes (p = 0.018), and body mass index (p = 0.044) after SCT compared with baseline. The Framingham general cardiovascular risk score (FGCRS) in males at five years after SCT projected a doubling (median 10.4% vs. 5.4%) in the 10-year risk of cardiovascular events. Females received HRT after SCT, and none had increased FGCRS. Chronic GVHD and C-reactive protein were not associated with CVRF at any time. All CVRFs stabilized between five and ten years after SCT. Thus, SCT survivors have sustained elevations in CVRFs. Males have a significantly increased risk of cardiovascular events in their second and third decade after SCT.

AB - Long-term survivors of allogeneic stem cell transplantation (SCT) have increased risk of cardiovascular disease. We retrospectively studied cardiovascular risk factors (CVRFs) in 109 SCT survivors (62 males, 47 females; median age 34 years) five years or more after bone marrow (15) or T cell-depleted peripheral blood (94) SCT for CML (56), acute leukemia (29), MDS (13), and others (11). One death and two cardiovascular events were reported. At five and ten years after SCT, respectively, 44% and 52% had abnormal lipid profiles; 23% of 5-year survivors met the Adult Treatment Panel III threshold for dyslipidemia treatment, which is substantially higher than the age-matched general population. There were significant increases in prevalence of hypertension (p < 0.001), diabetes (p = 0.018), and body mass index (p = 0.044) after SCT compared with baseline. The Framingham general cardiovascular risk score (FGCRS) in males at five years after SCT projected a doubling (median 10.4% vs. 5.4%) in the 10-year risk of cardiovascular events. Females received HRT after SCT, and none had increased FGCRS. Chronic GVHD and C-reactive protein were not associated with CVRF at any time. All CVRFs stabilized between five and ten years after SCT. Thus, SCT survivors have sustained elevations in CVRFs. Males have a significantly increased risk of cardiovascular events in their second and third decade after SCT.

UR - http://www.scopus.com/inward/record.url?scp=84896732181&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84896732181&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2013.07.003

DO - 10.1016/j.exphem.2013.07.003

M3 - Article

C2 - 24141092

AN - SCOPUS:84896732181

VL - 42

SP - 101

EP - 113

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 2

ER -